A Selective Summary of Psychopharmacology Research Published in First Half of 2015
https://doi.org/10.30834/KJP.28.1.2015.27
HTML
PDF

References

Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346(4):36-46.

Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer’s disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190(4):359–60.10

Ishii N, Terao T, Araki Y, et al. Low risk of male suicide and lithium in drinking water. J Clin Psychiatry 2015; 76(3):319–26.

Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry 2012; 200: 137–42.

Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman AS, et al. .Adherence to antidepressant therapy and mortality rates in ischemic heart disease: cohort study. Br J Psychiatry 2015; 206(4):297-301.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446–57.

Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011; 108(22):9262-7.

Eyre HA, Air T, Proctor S, Rositano S, Baune BT. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry 2015; 57:11-6.

O’Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito ML, Ikomi J et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry 2015; 76(2):e207–e13.

Young SL, Taylor M, Lawrie SM. “First do no harmâ€: A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015; 29(4):353-62.

Waddell L, Taylor MA. New self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 2008; 22:238–43.

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47, 351–54.

McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45(4):693-704.

Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry 2015; 172(1):41-51.

Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M,et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ 2014; 349:g5205.

Sim F, Sweetman I, Kapur S, Patel MX. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol 2015; 29(2):212-23.

Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72(2):136-42.

Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry 2015; 72(2):110-1.

Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Björkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41(3):656-63.

Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomized controlled trial. Lancet. [cited 2015 April 30] Available from:www.thelancet.com/ http://dx.doi.org/10.1016/S0140-6736(14)62222-4